| Status: Under consideration by AWMSG Scrutiny Panel | |
Treatment of immune checkpoint inhibitor (ICI) induced grade 3-4 pneumonitis, where symptoms have not responded to first line immunosuppression with corticosteroids. |
|
Medicine details |
|
| Medicine name | tocilizumab |
| Formulation | concentrate for solution for infusion |
| Reference number | 7243 |
| Indication | As above |
| Company | various |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 11/09/2025 |